TIS tissue therapies limited

questions for the agm, page-42

  1. 235 Posts.
    lightbulb Created with Sketch. 33
    GKM/Gorsen/Matt666
    I can also confirm that SM advised the meeting the expectation was "a few hundred thousand" for calendar year 2012; this was in response to a specific question asked by Horsefly on what we could expect.
    There are a number of reasons, including (from my understanding) SM ongoing negotiations to have our product included under the various National Health Schemes for money back. This I understood to be the equivalents of our PBS/Medicare in the various EU jurisdictions. With the current EU crisis dollars are being slashed everywhere; including health and the process will take time. Our advantage in convincing the various decision makers is that our product is going to save them money. There will of course be cash sales, but the larger part of our target consumers in Europe are going to want it at PBS type rates. $1,000 for the full 10 week course will be out of the reach of most if they have to pay the full cost themselves. There is also time required for market penetration.
    I am hopeful, like everyone else, once the product is released to market they will all beat a track to our door.
    Re whether there there is a contract/agreement signed with Quintiles, in discussion with the Chairman after the meeting he indicated it was firm and was for an initial three years.

    Cheers
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.